Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
boston blog main
boston top stories
life sciences
nash
5
×
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
5
×
san francisco top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
celgene
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
nonalcoholic steatohepatitis
aducanumab
biogen
clinical trials
fail
genfit
gilead sciences
intercept pharmaceuticals
liver
madrigal pharmaceuticals
What
bio
drug
roundup
approved
biogen
disease
liver
nash
new
news
week
adu
aducanumab
advanced
allogene
alnylam’s
alzheimer’s
amyloid
angst
approval
bagged
beats
bff
bids
billions
biogen’s
brammer
cancer
complicated
conference
crispr
data
deals
depression
devoted
dire
diversity
easl
effects
failure
Language
Current search:
nash
×
photo
×
" san francisco blog main "
×
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More